Según datos difundidos por la London School of Hygiene & Tropical Medicine, actualmente existen 119 proyectos que buscan la fórmula para inmunizar contra la enfermedad causada por el virus SARS-CoV-2. El más avanzado es un proyecto chino, dirigido principalmente por la empresa CanSino, que está realizando ensayos clínicos de fase I y de fase II. Fuente: [AFP]
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FN2NIMIA7VHNNEJM5RJ7E77VU4.jpg)
:quality(75)/dvgnzpfv30f28.cloudfront.net/04-28-2020/t_0cfa2f31b6af4c9488c6b825a40e0150_name_119_PROYECTOS.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/QEB3P7MEVBEAHMB3FUBL27TTWY.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Junxv1Eh/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/DnTcXzje/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UZ33FKQGUZAUBIDC7WT3XC2MLY.png)
:quality(75)/cdn.jwplayer.com/v2/media/jvOyeiFV/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/HfmBEwSB/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/PKfylBxC/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/QEB3P7MEVBEAHMB3FUBL27TTWY.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/1xcF1Rg7/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/WVUXO4EV2ZFZVDLFIKR2LU5PZU.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/whZALDRw/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FN2NIMIA7VHNNEJM5RJ7E77VU4.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Junxv1Eh/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/DnTcXzje/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/nrPzJ4gj/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/1QmqNzz7/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/MZVlh9r6/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/E4Quiira/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FJHXJROFRFFQHON3TLN4PCGX2E.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/koNs9MA2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/6bLTGi5d/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/KgeU8b6Q/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/a6mwPQ4X/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X3PAJUVAAFHRXHUYV5TON7UAAY.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/5MX44LCM7BFEVHZQU33WFPMZFE.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/aIjZ5WWB/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/juAVPNx9/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/c0S03whF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/azLadx4o/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FQ5XSTUGQ5DI3DYDC3MUSLQL6A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9a1H4G0a/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/QYPNFGK56RE7FB6OYBZFBZOR6M.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/8j1uxDqb/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/ZxUTUGfS/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/yOEdb2ys/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/JW2JBE7IBZEY5NR2VH4KVTPGZ4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/42WZKDIDGVA6VKQDF75376W2CA.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ENCJ6JEIFZHT5E6UXK3KZ5RCUU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UZ27WLDNBFBCPCMLG42DQCNJYA.png)